Trial · NCT02556788
Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
NCT02556788, Phase 3, Completed, Galderma R&D; results first posted 2019-09-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris. Trials, record NCT02556788. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02556788
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris
- NCT number
- NCT02556788
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 1,212 participants, actual
- Lead sponsor
- Galderma R&D
- Conditions
- Acne Vulgaris
- Interventions
- CD5789 (trifarotene) 50µg/g Cream, Placebo Cream
- First posted
- 2015-09-22
- Last updated
- 2019-11-12
- Results first posted
- 2019-09-03
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) | From Baseline to Week 12 | Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) | From Baseline to Week 12 | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) | CD5789 (Trifarotene) 50µg/g Cream | 255 | Participants | ||
| Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) | Placebo Cream | 157 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | CD5789 (Trifarotene) 50µg/g Cream | 602 | |
| Overall Study | STARTED | Placebo Cream | 610 | |
| Overall Study | COMPLETED | CD5789 (Trifarotene) 50µg/g Cream | 558 | |
| Overall Study | COMPLETED | Placebo Cream | 573 | |
| Overall Study | NOT COMPLETED | CD5789 (Trifarotene) 50µg/g Cream | 44 | |
| Overall Study | NOT COMPLETED | Placebo Cream | 37 |
Source ClinicalTrials.gov
Adverse events52
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Sunburn | Injury, poisoning and procedural complications | CD5789 (Trifarotene) 50µg/g Cream | 2 | 602 | |
| other | Sunburn | Injury, poisoning and procedural complications | Placebo Cream | 0 | 610 | |
| other | Drug Administered at Inappropriate Site | Injury, poisoning and procedural complications | CD5789 (Trifarotene) 50µg/g Cream | 1 | 602 | |
| other | Drug Administered at Inappropriate Site | Injury, poisoning and procedural complications | Placebo Cream | 0 | 610 | |
| other | Blood Bilirubin Increased | Investigations | CD5789 (Trifarotene) 50µg/g Cream | 0 | 602 | |
| other | Blood Bilirubin Increased | Investigations | Placebo Cream | 1 | 610 | |
| other | Blood Creatinine Increased | Investigations | CD5789 (Trifarotene) 50µg/g Cream | 0 | 602 | |
| other | Blood Creatinine Increased | Investigations | Placebo Cream | 1 | 610 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | CD5789 (Trifarotene) 50µg/g Cream | 1 | 602 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Placebo Cream | 0 | 610 |
1 to 10 of 52Source ClinicalTrials.gov
See all 52 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | CD5789 (Trifarotene) 50µg/g Cream | 0 | 602 |
| Total, all-cause mortality | Placebo Cream | 0 | 610 |
| Total, other adverse events | CD5789 (Trifarotene) 50µg/g Cream | 21 | 602 |
| Total, other adverse events | Placebo Cream | 5 | 610 |
| Total, serious adverse events | CD5789 (Trifarotene) 50µg/g Cream | 2 | 602 |
| Total, serious adverse events | Placebo Cream | 4 | 610 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) | Trial comparisons |
| CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: deaths from any cause | Trial comparisons |
| CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02556788
GET https://conductscience.org/api/trials/v1/NCT02556788/events?page=2